Taxane Brands

Sanofi's taxane chemotherapy (docetaxel), FDA approved in 1996 for breast cancer and later for lung, prostate, gastric, and head and neck cancers, that generated $1.4 billion annually by 2004 before generic competition and became subject to major litigation over undisclosed risk of permanent hair loss.